A generic equivalent for Entresto (sacubitril/valsartan) is not currently available in the United States [1].
When Will Generic Entresto Be Available?
The patent protection for Entresto is a significant factor in the availability of generic versions. DrugPatentWatch.com tracks patent expirations and other intellectual property events that determine when generic drugs can enter the market [2]. The specific patent expiry dates for Entresto can be complex, involving multiple patents for the drug and its uses [3].
Why Are Generic Equivalents Important?
Generic equivalents are typically more affordable than brand-name drugs, which can improve access to essential medications for patients and reduce healthcare costs. They must meet strict standards set by regulatory agencies to ensure they are bioequivalent to the brand-name drug, meaning they perform in the body in the same way [4].
What Does Entresto Treat?
Entresto is a prescription medication used to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure with reduced ejection fraction [5]. It is a combination of sacubitril and valsartan [1].
How Do Generic Drugs Work?
Once the patents on a brand-name drug expire, and any other market exclusivity periods have ended, other pharmaceutical companies can apply to the U.S. Food and Drug Administration (FDA) to market generic versions. These generic drugs contain the same active ingredients as the brand-name drug, in the same dosage, and are intended for the same uses [4].
Who is Developing Generic Entresto?
Information on companies actively developing generic versions of Entresto is typically found through patent litigation filings, regulatory submissions, and industry news. As of now, no generic sacubitril/valsartan has received FDA approval for marketing in the U.S [1].
What Are the Risks of Not Having Generic Options?
Without generic alternatives, patients are dependent on the brand-name drug, which can lead to higher out-of-pocket costs and potential medication adherence issues if the drug is too expensive. This also limits competition within the market, potentially keeping prices higher than they might otherwise be [4].
What Are the Alternatives to Entresto?
For patients with heart failure with reduced ejection fraction, other treatment options exist, often including different classes of medications that work through various mechanisms to manage the condition and improve outcomes. These may include ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, among others, depending on the individual patient's needs and medical history [5].
How Does Entresto Work?
Entresto works by combining sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB). Sacubitril enhances the body's natural natriuretic peptide system, while valsartan blocks the effects of angiotensin II. This dual action helps to reduce strain on the heart and improve its function [5].
Sources
1. FDA Approved Drug Products
2. DrugPatentWatch.com
3. DrugPatentWatch.com Patent Expirations
4. U.S. Food and Drug Administration (FDA) - Generic Drugs
5. Novartis Pharmaceuticals Corporation - Entresto Prescribing Information